FDA Clears Roche Elecsys pTau217 and C2N PrecivityAD2 Alzheimer's Blood Tests The FDA has cleared Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2, bringing FDA-cleared Alzheimer's blood tests to four, with PrecivityAD2 indicated for adults as young as 40. The U.S. Food and Drug Administration has cleared two new Alzheimer's blood tests designed to help clinicians assess whether a person with cognitive symptoms has amyloid pathology, a hallmark of Alzheimer's disease. The cleared tests are Roche's Elecsys pTau217 and C2N Diagnostics' PrecivityAD2, bringing the number of FDA-cleared Alzheimer's blood tests to four. PrecivityAD2 is the first such test indicated for symptomatic adults as young as 40, while Roche's test is for adults 55 and older with signs, symptoms or complaints of cognitive decline. Neither test is intended to diagnose Alzheimer's disease on its own.The FDA and the manufacturers stress that results must be interpreted with symptoms, medical history and other clinical findings. The tests remain triage tools, not stand-alone diagnoses, and any promotion as a screening test for healthy adults would fall outside the cleared indications.Elecsys pTau217 measures a single blood biomarker, phosphorylated tau 217, and returns positive, intermediate or negative results. PrecivityAD2 combines an amyloid-beta 42/40 ratio with a p-tau217/np-tau217 ratio.In a validation study of 1,142 people with cognitive symptoms, PrecivityAD2 had a positive predictive value of 97.6% and a negative predictive value of 93.1% against amyloid PET scans or cerebrospinal fluid biomarkers. Roche reported that Elecsys pTau217 agreed with amyloid PET results in about 88% of people with cognitive impairment and 91% of people without cognitive impairment in a study of more than 2,100 adults. C2N says the FDA-cleared version is expected later in 2026.The practical appeal is that blood testing is less invasive and potentially more accessible than PET imaging or lumbar puncture. Roche's cobas network gives Elecsys pTau217 a primary-care distribution advantage. The test is designed to run on Roche's existing cobas laboratory instruments, and the company says more than 4,500 of those systems are already installed in U.S. laboratories.That installed base lowers the practical barrier to adoption, allowing laboratories and health systems to add the test without building new testing capacity. If clinicians use it in primary care as well as specialist settings, it could shift biomarker assessment earlier in the diagnostic pathway, which is where many patients first raise cognitive concerns.PrecivityAD2's indication for symptomatic adults ages 40 and older gives C2N a differentiating claim, but it is not a screening approval. Dr. Dung Trinh, an internist not involved with either test, said blood biomarkers could help some symptomatic younger adults get an explanation earlier, but they are not meant for routine screening of healthy people in their 40s.Dr. Trinh cautioned that Alzheimer-related amyloid pathology is less common at younger ages, so the pre-test probability is lower and interpretation depends heavily on the broader clinical picture. He also noted that very young patients were relatively few in validation studies, meaning the overall 97.6% positive predictive value may not apply identically to adults in their 40s. Positive results in younger patients can have profound work, family, financial and emotional consequences, making patient selection and counselling essential.The clearest clinical role for both tests is triage: identify people in whom amyloid pathology is unlikely, flag those who need specialist evaluation, and reduce unnecessary PET or CSF testing for clear negatives. Roche explicitly frames Elecsys pTau217 as a way to help clinicians decide whether additional evaluation or referral is appropriate.The unresolved questions are real: how intermediate results should be managed, how reimbursement will work, and when confirmatory imaging remains necessary. With the earlier Lumipulse test already cleared, the market is becoming more competitive, but the evidence and distribution advantages are uneven.Patients with cognitive symptoms should ask a physician whether amyloid blood testing fits their clinical evaluation. A clearly negative result can make amyloid pathology less likely and shift attention to other causes; a positive or intermediate result still requires clinical workup and, often, specialist assessment.Adults in their 40s should not treat PrecivityAD2 as a screening check. Its 40-and-older indication applies only when a person already has signs or symptoms of cognitive impairment and is being evaluated; sleep, mood, metabolic and neurologic causes should also be considered.Primary care practices that use Elecsys pTau217 should use its positive, negative and intermediate categories to guide referral decisions, but build a clear follow-up path for intermediate results rather than treating the test as a diagnosis.The installed cobas base of more than 4,500 U.S. laboratories is the commercial asset for Roche and Eli Lilly to leverage, but clinician education must emphasize that the test is a gateway in the diagnostic pathway, not a standalone diagnosis. Generating more validation data in adults in their 40s will be critical to defending the first-in-class younger indication.Blood-based biomarker adoption could shift volume away from amyloid PET and CSF referral pathways, creating commercial pressure on established assessment routes. Reimbursement and integration into routine care remain unresolved, and patients and clinicians may misunderstand positive or intermediate blood results as an Alzheimer's diagnosis, particularly in younger adults where implications for work and family are severe.Single-biomarker pTau217 testing on widely installed cobas infrastructure could move amyloid assessment earlier into primary care and reduce reliance on PET and CSF procedures for initial triage. The clearances expand the addressable market to symptomatic adults 55 and older and to a first clear indication for ages 40 and older, with Roche's U.S. cobas footprint and C2N's differentiated label supporting adoption.